Why the study?
Does acute versus chronic aspirin treatment modify nitric oxide synthase activity in platelets from healthy subjects?
Does acute versus chronic aspirin treatment modify nitric oxide synthase activity in platelets from healthy subjects?
Aspirin exerts divergent effects on basal and beta-adrenoceptor-stimulated platelet NOS activity depending on acute versus chronic administration, which may have clinical relevance for antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Acute versus chronic aspirin may differentially modulate platelet NOS activity; hypothesis-generating for antiplatelet mechanisms, should not change practice.
OBJECTIVE: We examined the effects of aspirin on basal and beta-adrenoceptor (beta-AR)-mediated nitric oxide synthase (NOS) activity in normal platelets. METHODS: NOS activity was determined from the conversion of L-[3H]arginine to L-[3H]citrulline, both basally and following beta-AR stimulation, in platelets from healthy human subjects following both short- and long-term aspirin administration. RESULTS: Basal L-[3H]citrulline increased following aspirin 800 mg administered intravenously in vivo, from 0.31+/-0.12 to 0.76+/-0.14 pmol/10(8) platelets (P<0.01). Isoproterenol at 1 micromol/l increased platelet NOS activity before but not following intravenous aspirin. After short-term in vitro treatment with aspirin 10 micromol/l, 400 micromol/l or 4 mmol/l, basal platelet L-[3H]citrulline increased similarly, an effect not seen with indomethacin 100 micromol/l or ibuprofen 10 micromol/l. Platelet NOS activity was not increased by albuterol 1 micromol/l, in the presence of indomethacin, ibuprofen or aspirin in vitro. By contrast, oral aspirin 75 mg daily for 14 days did not affect basal platelet NOS activity, but abolished beta-adrenergic NOS activation. CONCLUSIONS: Aspirin activates basal platelet NOS acutely, but not chronically, through a mechanism independent of cyclooxygenase (COX) inhibition. By contrast, both short- and long-term aspirin treatment inhibit platelet beta-adrenergic NOS activation by a COX-dependent mechanism. This indicates that aspirin exerts divergent effects on basal and beta-AR-stimulated platelet NOS activity, which are likely to be of clinical relevance.
No takes yet. Share an insight, caveat, or question.
Peter O’Kane (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: